Global Radionuclide Drug Conjugates (RDC) Supply, Demand and Key Producers, 2023-2029
The global Radionuclide Drug Conjugates (RDC) market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
RDC therapy combines radionuclides with specific monoclonal antibodies to achieve the dual advantages of precise targeting and powerful killing of tumor cells. It can highly concentrate the energy released by radionuclides within several times the diameter of cancer cells, thereby minimizing damage to surrounding normal tissues. This enables it to effectively kill cancer cells while protecting normal tissues, so it has good curative effect and low adverse reactions, and can prolong the survival of patients with advanced cancer, which is of great significance to the treatment of advanced tumors.
According to the function, RDC can be divided into RDC for diagnosis and RDC for treatment, and the functional classification is closely related to the type of nuclide.
At present, the most widely used nuclide for diagnosis is 99mTc, and the nuclide for treatment is 131I, 90Y and 223Ra. Radionuclide technology provides unique advantages for early diagnosis and targeted therapy of tumors, but the acquisition and preparation technology of radionuclide still limits its wider clinical application and needs further research and development.
According to different targeting ligands, RDC can be subdivided into: antibody-conjugated nuclide drugs (ARC) and small molecule-conjugated nuclide drugs (including polypeptide-conjugated nuclide drugs-PRC).
According to the data of the Global New Drug Information Database, among the RDC drugs currently in clinical research and on the market, the main research targets are CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), SSTR (somatostatin receptor ); the main indications are concentrated in neuroendocrine tumors, prostate cancer, and renal cell carcinoma.
This report studies the global Radionuclide Drug Conjugates (RDC) demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Radionuclide Drug Conjugates (RDC), and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Radionuclide Drug Conjugates (RDC) that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Radionuclide Drug Conjugates (RDC) total market, 2018-2029, (USD Million)
Global Radionuclide Drug Conjugates (RDC) total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Radionuclide Drug Conjugates (RDC) total market, key domestic companies and share, (USD Million)
Global Radionuclide Drug Conjugates (RDC) revenue by player and market share 2018-2023, (USD Million)
Global Radionuclide Drug Conjugates (RDC) total market by Type, CAGR, 2018-2029, (USD Million)
Global Radionuclide Drug Conjugates (RDC) total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Radionuclide Drug Conjugates (RDC) market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Uihc Pet Imaging and Grand Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Radionuclide Drug Conjugates (RDC) market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Radionuclide Drug Conjugates (RDC) Market, By Region:
1. How big is the global Radionuclide Drug Conjugates (RDC) market?
2. What is the demand of the global Radionuclide Drug Conjugates (RDC) market?
3. What is the year over year growth of the global Radionuclide Drug Conjugates (RDC) market?
4. What is the total value of the global Radionuclide Drug Conjugates (RDC) market?
5. Who are the major players in the global Radionuclide Drug Conjugates (RDC) market?
6. What are the growth factors driving the market demand?
RDC therapy combines radionuclides with specific monoclonal antibodies to achieve the dual advantages of precise targeting and powerful killing of tumor cells. It can highly concentrate the energy released by radionuclides within several times the diameter of cancer cells, thereby minimizing damage to surrounding normal tissues. This enables it to effectively kill cancer cells while protecting normal tissues, so it has good curative effect and low adverse reactions, and can prolong the survival of patients with advanced cancer, which is of great significance to the treatment of advanced tumors.
According to the function, RDC can be divided into RDC for diagnosis and RDC for treatment, and the functional classification is closely related to the type of nuclide.
At present, the most widely used nuclide for diagnosis is 99mTc, and the nuclide for treatment is 131I, 90Y and 223Ra. Radionuclide technology provides unique advantages for early diagnosis and targeted therapy of tumors, but the acquisition and preparation technology of radionuclide still limits its wider clinical application and needs further research and development.
According to different targeting ligands, RDC can be subdivided into: antibody-conjugated nuclide drugs (ARC) and small molecule-conjugated nuclide drugs (including polypeptide-conjugated nuclide drugs-PRC).
According to the data of the Global New Drug Information Database, among the RDC drugs currently in clinical research and on the market, the main research targets are CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), SSTR (somatostatin receptor ); the main indications are concentrated in neuroendocrine tumors, prostate cancer, and renal cell carcinoma.
This report studies the global Radionuclide Drug Conjugates (RDC) demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Radionuclide Drug Conjugates (RDC), and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Radionuclide Drug Conjugates (RDC) that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Radionuclide Drug Conjugates (RDC) total market, 2018-2029, (USD Million)
Global Radionuclide Drug Conjugates (RDC) total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Radionuclide Drug Conjugates (RDC) total market, key domestic companies and share, (USD Million)
Global Radionuclide Drug Conjugates (RDC) revenue by player and market share 2018-2023, (USD Million)
Global Radionuclide Drug Conjugates (RDC) total market by Type, CAGR, 2018-2029, (USD Million)
Global Radionuclide Drug Conjugates (RDC) total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Radionuclide Drug Conjugates (RDC) market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Uihc Pet Imaging and Grand Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Radionuclide Drug Conjugates (RDC) market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Radionuclide Drug Conjugates (RDC) Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Antibody Radionuclide Conjugates (ARC)
- Peptide Radionuclide Conjugates (PRC)
- Small Molecular Radionuclide Conjugates (SMRC)
- Neuroendocrine Tumors
- Prostate Cancer
- Renal Cell Carcinoma
- POINT Biopharma
- Telix
- ITM AG
- Bayer AG
- Novartis
- Lantheus
- Curium Pharma
- Uihc Pet Imaging
- Grand Pharma
- BoomRay Pharmaceuticals
- SmartNuclide Biopharma
- Hengrui Medicine
- Yunnan Baiyao Group
- Sinotau
- Hexin Pharmaceutical
- Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
1. How big is the global Radionuclide Drug Conjugates (RDC) market?
2. What is the demand of the global Radionuclide Drug Conjugates (RDC) market?
3. What is the year over year growth of the global Radionuclide Drug Conjugates (RDC) market?
4. What is the total value of the global Radionuclide Drug Conjugates (RDC) market?
5. Who are the major players in the global Radionuclide Drug Conjugates (RDC) market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Radionuclide Drug Conjugates (RDC) Introduction
1.2 World Radionuclide Drug Conjugates (RDC) Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Radionuclide Drug Conjugates (RDC) Total Market by Region (by Headquarter Location)
1.3.1 World Radionuclide Drug Conjugates (RDC) Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.3.3 China Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.3.4 Europe Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.3.5 Japan Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.3.6 South Korea Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.3.7 ASEAN Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.3.8 India Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Radionuclide Drug Conjugates (RDC) Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Radionuclide Drug Conjugates (RDC) Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.2 World Radionuclide Drug Conjugates (RDC) Consumption Value by Region
2.2.1 World Radionuclide Drug Conjugates (RDC) Consumption Value by Region (2018-2023)
2.2.2 World Radionuclide Drug Conjugates (RDC) Consumption Value Forecast by Region (2024-2029)
2.3 United States Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.4 China Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.5 Europe Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.6 Japan Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.7 South Korea Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.8 ASEAN Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.9 India Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
3 WORLD RADIONUCLIDE DRUG CONJUGATES (RDC) COMPANIES COMPETITIVE ANALYSIS
3.1 World Radionuclide Drug Conjugates (RDC) Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Radionuclide Drug Conjugates (RDC) Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Radionuclide Drug Conjugates (RDC) in 2022
3.2.3 Global Concentration Ratios (CR8) for Radionuclide Drug Conjugates (RDC) in 2022
3.3 Radionuclide Drug Conjugates (RDC) Company Evaluation Quadrant
3.4 Radionuclide Drug Conjugates (RDC) Market: Overall Company Footprint Analysis
3.4.1 Radionuclide Drug Conjugates (RDC) Market: Region Footprint
3.4.2 Radionuclide Drug Conjugates (RDC) Market: Company Product Type Footprint
3.4.3 Radionuclide Drug Conjugates (RDC) Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Radionuclide Drug Conjugates (RDC) Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Radionuclide Drug Conjugates (RDC) Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Radionuclide Drug Conjugates (RDC) Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Radionuclide Drug Conjugates (RDC) Consumption Value Comparison
4.2.1 United States VS China: Radionuclide Drug Conjugates (RDC) Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Radionuclide Drug Conjugates (RDC) Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Radionuclide Drug Conjugates (RDC) Companies and Market Share, 2018-2023
4.3.1 United States Based Radionuclide Drug Conjugates (RDC) Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Radionuclide Drug Conjugates (RDC) Revenue, (2018-2023)
4.4 China Based Companies Radionuclide Drug Conjugates (RDC) Revenue and Market Share, 2018-2023
4.4.1 China Based Radionuclide Drug Conjugates (RDC) Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Radionuclide Drug Conjugates (RDC) Revenue, (2018-2023)
4.5 Rest of World Based Radionuclide Drug Conjugates (RDC) Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Radionuclide Drug Conjugates (RDC) Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Radionuclide Drug Conjugates (RDC) Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Radionuclide Drug Conjugates (RDC) Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Antibody Radionuclide Conjugates (ARC)
5.2.2 Peptide Radionuclide Conjugates (PRC)
5.2.3 Small Molecular Radionuclide Conjugates (SMRC)
5.3 Market Segment by Type
5.3.1 World Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023)
5.3.2 World Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2029)
5.3.3 World Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Radionuclide Drug Conjugates (RDC) Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Neuroendocrine Tumors
6.2.2 Prostate Cancer
6.2.3 Renal Cell Carcinoma
6.3 Market Segment by Application
6.3.1 World Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023)
6.3.2 World Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2029)
6.3.3 World Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 POINT Biopharma
7.1.1 POINT Biopharma Details
7.1.2 POINT Biopharma Major Business
7.1.3 POINT Biopharma Radionuclide Drug Conjugates (RDC) Product and Services
7.1.4 POINT Biopharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 POINT Biopharma Recent Developments/Updates
7.1.6 POINT Biopharma Competitive Strengths & Weaknesses
7.2 Telix
7.2.1 Telix Details
7.2.2 Telix Major Business
7.2.3 Telix Radionuclide Drug Conjugates (RDC) Product and Services
7.2.4 Telix Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Telix Recent Developments/Updates
7.2.6 Telix Competitive Strengths & Weaknesses
7.3 ITM AG
7.3.1 ITM AG Details
7.3.2 ITM AG Major Business
7.3.3 ITM AG Radionuclide Drug Conjugates (RDC) Product and Services
7.3.4 ITM AG Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 ITM AG Recent Developments/Updates
7.3.6 ITM AG Competitive Strengths & Weaknesses
7.4 Bayer AG
7.4.1 Bayer AG Details
7.4.2 Bayer AG Major Business
7.4.3 Bayer AG Radionuclide Drug Conjugates (RDC) Product and Services
7.4.4 Bayer AG Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Bayer AG Recent Developments/Updates
7.4.6 Bayer AG Competitive Strengths & Weaknesses
7.5 Novartis
7.5.1 Novartis Details
7.5.2 Novartis Major Business
7.5.3 Novartis Radionuclide Drug Conjugates (RDC) Product and Services
7.5.4 Novartis Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Novartis Recent Developments/Updates
7.5.6 Novartis Competitive Strengths & Weaknesses
7.6 Lantheus
7.6.1 Lantheus Details
7.6.2 Lantheus Major Business
7.6.3 Lantheus Radionuclide Drug Conjugates (RDC) Product and Services
7.6.4 Lantheus Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Lantheus Recent Developments/Updates
7.6.6 Lantheus Competitive Strengths & Weaknesses
7.7 Curium Pharma
7.7.1 Curium Pharma Details
7.7.2 Curium Pharma Major Business
7.7.3 Curium Pharma Radionuclide Drug Conjugates (RDC) Product and Services
7.7.4 Curium Pharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Curium Pharma Recent Developments/Updates
7.7.6 Curium Pharma Competitive Strengths & Weaknesses
7.8 Uihc Pet Imaging
7.8.1 Uihc Pet Imaging Details
7.8.2 Uihc Pet Imaging Major Business
7.8.3 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Product and Services
7.8.4 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Uihc Pet Imaging Recent Developments/Updates
7.8.6 Uihc Pet Imaging Competitive Strengths & Weaknesses
7.9 Grand Pharma
7.9.1 Grand Pharma Details
7.9.2 Grand Pharma Major Business
7.9.3 Grand Pharma Radionuclide Drug Conjugates (RDC) Product and Services
7.9.4 Grand Pharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Grand Pharma Recent Developments/Updates
7.9.6 Grand Pharma Competitive Strengths & Weaknesses
7.10 BoomRay Pharmaceuticals
7.10.1 BoomRay Pharmaceuticals Details
7.10.2 BoomRay Pharmaceuticals Major Business
7.10.3 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Product and Services
7.10.4 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 BoomRay Pharmaceuticals Recent Developments/Updates
7.10.6 BoomRay Pharmaceuticals Competitive Strengths & Weaknesses
7.11 SmartNuclide Biopharma
7.11.1 SmartNuclide Biopharma Details
7.11.2 SmartNuclide Biopharma Major Business
7.11.3 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Product and Services
7.11.4 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 SmartNuclide Biopharma Recent Developments/Updates
7.11.6 SmartNuclide Biopharma Competitive Strengths & Weaknesses
7.12 Hengrui Medicine
7.12.1 Hengrui Medicine Details
7.12.2 Hengrui Medicine Major Business
7.12.3 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Product and Services
7.12.4 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Hengrui Medicine Recent Developments/Updates
7.12.6 Hengrui Medicine Competitive Strengths & Weaknesses
7.13 Yunnan Baiyao Group
7.13.1 Yunnan Baiyao Group Details
7.13.2 Yunnan Baiyao Group Major Business
7.13.3 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Product and Services
7.13.4 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Yunnan Baiyao Group Recent Developments/Updates
7.13.6 Yunnan Baiyao Group Competitive Strengths & Weaknesses
7.14 Sinotau
7.14.1 Sinotau Details
7.14.2 Sinotau Major Business
7.14.3 Sinotau Radionuclide Drug Conjugates (RDC) Product and Services
7.14.4 Sinotau Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Sinotau Recent Developments/Updates
7.14.6 Sinotau Competitive Strengths & Weaknesses
7.15 Hexin Pharmaceutical
7.15.1 Hexin Pharmaceutical Details
7.15.2 Hexin Pharmaceutical Major Business
7.15.3 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Product and Services
7.15.4 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Hexin Pharmaceutical Recent Developments/Updates
7.15.6 Hexin Pharmaceutical Competitive Strengths & Weaknesses
7.16 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
7.16.1 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Details
7.16.2 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Major Business
7.16.3 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Product and Services
7.16.4 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Recent Developments/Updates
7.16.6 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Radionuclide Drug Conjugates (RDC) Industry Chain
8.2 Radionuclide Drug Conjugates (RDC) Upstream Analysis
8.3 Radionuclide Drug Conjugates (RDC) Midstream Analysis
8.4 Radionuclide Drug Conjugates (RDC) Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Radionuclide Drug Conjugates (RDC) Introduction
1.2 World Radionuclide Drug Conjugates (RDC) Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Radionuclide Drug Conjugates (RDC) Total Market by Region (by Headquarter Location)
1.3.1 World Radionuclide Drug Conjugates (RDC) Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.3.3 China Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.3.4 Europe Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.3.5 Japan Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.3.6 South Korea Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.3.7 ASEAN Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.3.8 India Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Radionuclide Drug Conjugates (RDC) Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Radionuclide Drug Conjugates (RDC) Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.2 World Radionuclide Drug Conjugates (RDC) Consumption Value by Region
2.2.1 World Radionuclide Drug Conjugates (RDC) Consumption Value by Region (2018-2023)
2.2.2 World Radionuclide Drug Conjugates (RDC) Consumption Value Forecast by Region (2024-2029)
2.3 United States Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.4 China Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.5 Europe Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.6 Japan Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.7 South Korea Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.8 ASEAN Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
2.9 India Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029)
3 WORLD RADIONUCLIDE DRUG CONJUGATES (RDC) COMPANIES COMPETITIVE ANALYSIS
3.1 World Radionuclide Drug Conjugates (RDC) Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Radionuclide Drug Conjugates (RDC) Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Radionuclide Drug Conjugates (RDC) in 2022
3.2.3 Global Concentration Ratios (CR8) for Radionuclide Drug Conjugates (RDC) in 2022
3.3 Radionuclide Drug Conjugates (RDC) Company Evaluation Quadrant
3.4 Radionuclide Drug Conjugates (RDC) Market: Overall Company Footprint Analysis
3.4.1 Radionuclide Drug Conjugates (RDC) Market: Region Footprint
3.4.2 Radionuclide Drug Conjugates (RDC) Market: Company Product Type Footprint
3.4.3 Radionuclide Drug Conjugates (RDC) Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Radionuclide Drug Conjugates (RDC) Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Radionuclide Drug Conjugates (RDC) Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Radionuclide Drug Conjugates (RDC) Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Radionuclide Drug Conjugates (RDC) Consumption Value Comparison
4.2.1 United States VS China: Radionuclide Drug Conjugates (RDC) Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Radionuclide Drug Conjugates (RDC) Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Radionuclide Drug Conjugates (RDC) Companies and Market Share, 2018-2023
4.3.1 United States Based Radionuclide Drug Conjugates (RDC) Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Radionuclide Drug Conjugates (RDC) Revenue, (2018-2023)
4.4 China Based Companies Radionuclide Drug Conjugates (RDC) Revenue and Market Share, 2018-2023
4.4.1 China Based Radionuclide Drug Conjugates (RDC) Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Radionuclide Drug Conjugates (RDC) Revenue, (2018-2023)
4.5 Rest of World Based Radionuclide Drug Conjugates (RDC) Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Radionuclide Drug Conjugates (RDC) Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Radionuclide Drug Conjugates (RDC) Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Radionuclide Drug Conjugates (RDC) Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Antibody Radionuclide Conjugates (ARC)
5.2.2 Peptide Radionuclide Conjugates (PRC)
5.2.3 Small Molecular Radionuclide Conjugates (SMRC)
5.3 Market Segment by Type
5.3.1 World Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023)
5.3.2 World Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2029)
5.3.3 World Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Radionuclide Drug Conjugates (RDC) Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Neuroendocrine Tumors
6.2.2 Prostate Cancer
6.2.3 Renal Cell Carcinoma
6.3 Market Segment by Application
6.3.1 World Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023)
6.3.2 World Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2029)
6.3.3 World Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 POINT Biopharma
7.1.1 POINT Biopharma Details
7.1.2 POINT Biopharma Major Business
7.1.3 POINT Biopharma Radionuclide Drug Conjugates (RDC) Product and Services
7.1.4 POINT Biopharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 POINT Biopharma Recent Developments/Updates
7.1.6 POINT Biopharma Competitive Strengths & Weaknesses
7.2 Telix
7.2.1 Telix Details
7.2.2 Telix Major Business
7.2.3 Telix Radionuclide Drug Conjugates (RDC) Product and Services
7.2.4 Telix Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Telix Recent Developments/Updates
7.2.6 Telix Competitive Strengths & Weaknesses
7.3 ITM AG
7.3.1 ITM AG Details
7.3.2 ITM AG Major Business
7.3.3 ITM AG Radionuclide Drug Conjugates (RDC) Product and Services
7.3.4 ITM AG Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 ITM AG Recent Developments/Updates
7.3.6 ITM AG Competitive Strengths & Weaknesses
7.4 Bayer AG
7.4.1 Bayer AG Details
7.4.2 Bayer AG Major Business
7.4.3 Bayer AG Radionuclide Drug Conjugates (RDC) Product and Services
7.4.4 Bayer AG Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Bayer AG Recent Developments/Updates
7.4.6 Bayer AG Competitive Strengths & Weaknesses
7.5 Novartis
7.5.1 Novartis Details
7.5.2 Novartis Major Business
7.5.3 Novartis Radionuclide Drug Conjugates (RDC) Product and Services
7.5.4 Novartis Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Novartis Recent Developments/Updates
7.5.6 Novartis Competitive Strengths & Weaknesses
7.6 Lantheus
7.6.1 Lantheus Details
7.6.2 Lantheus Major Business
7.6.3 Lantheus Radionuclide Drug Conjugates (RDC) Product and Services
7.6.4 Lantheus Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Lantheus Recent Developments/Updates
7.6.6 Lantheus Competitive Strengths & Weaknesses
7.7 Curium Pharma
7.7.1 Curium Pharma Details
7.7.2 Curium Pharma Major Business
7.7.3 Curium Pharma Radionuclide Drug Conjugates (RDC) Product and Services
7.7.4 Curium Pharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Curium Pharma Recent Developments/Updates
7.7.6 Curium Pharma Competitive Strengths & Weaknesses
7.8 Uihc Pet Imaging
7.8.1 Uihc Pet Imaging Details
7.8.2 Uihc Pet Imaging Major Business
7.8.3 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Product and Services
7.8.4 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Uihc Pet Imaging Recent Developments/Updates
7.8.6 Uihc Pet Imaging Competitive Strengths & Weaknesses
7.9 Grand Pharma
7.9.1 Grand Pharma Details
7.9.2 Grand Pharma Major Business
7.9.3 Grand Pharma Radionuclide Drug Conjugates (RDC) Product and Services
7.9.4 Grand Pharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Grand Pharma Recent Developments/Updates
7.9.6 Grand Pharma Competitive Strengths & Weaknesses
7.10 BoomRay Pharmaceuticals
7.10.1 BoomRay Pharmaceuticals Details
7.10.2 BoomRay Pharmaceuticals Major Business
7.10.3 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Product and Services
7.10.4 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 BoomRay Pharmaceuticals Recent Developments/Updates
7.10.6 BoomRay Pharmaceuticals Competitive Strengths & Weaknesses
7.11 SmartNuclide Biopharma
7.11.1 SmartNuclide Biopharma Details
7.11.2 SmartNuclide Biopharma Major Business
7.11.3 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Product and Services
7.11.4 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 SmartNuclide Biopharma Recent Developments/Updates
7.11.6 SmartNuclide Biopharma Competitive Strengths & Weaknesses
7.12 Hengrui Medicine
7.12.1 Hengrui Medicine Details
7.12.2 Hengrui Medicine Major Business
7.12.3 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Product and Services
7.12.4 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Hengrui Medicine Recent Developments/Updates
7.12.6 Hengrui Medicine Competitive Strengths & Weaknesses
7.13 Yunnan Baiyao Group
7.13.1 Yunnan Baiyao Group Details
7.13.2 Yunnan Baiyao Group Major Business
7.13.3 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Product and Services
7.13.4 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Yunnan Baiyao Group Recent Developments/Updates
7.13.6 Yunnan Baiyao Group Competitive Strengths & Weaknesses
7.14 Sinotau
7.14.1 Sinotau Details
7.14.2 Sinotau Major Business
7.14.3 Sinotau Radionuclide Drug Conjugates (RDC) Product and Services
7.14.4 Sinotau Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Sinotau Recent Developments/Updates
7.14.6 Sinotau Competitive Strengths & Weaknesses
7.15 Hexin Pharmaceutical
7.15.1 Hexin Pharmaceutical Details
7.15.2 Hexin Pharmaceutical Major Business
7.15.3 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Product and Services
7.15.4 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Hexin Pharmaceutical Recent Developments/Updates
7.15.6 Hexin Pharmaceutical Competitive Strengths & Weaknesses
7.16 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
7.16.1 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Details
7.16.2 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Major Business
7.16.3 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Product and Services
7.16.4 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Recent Developments/Updates
7.16.6 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Radionuclide Drug Conjugates (RDC) Industry Chain
8.2 Radionuclide Drug Conjugates (RDC) Upstream Analysis
8.3 Radionuclide Drug Conjugates (RDC) Midstream Analysis
8.4 Radionuclide Drug Conjugates (RDC) Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Radionuclide Drug Conjugates (RDC) Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Radionuclide Drug Conjugates (RDC) Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Radionuclide Drug Conjugates (RDC) Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Radionuclide Drug Conjugates (RDC) Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Radionuclide Drug Conjugates (RDC) Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Radionuclide Drug Conjugates (RDC) Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Radionuclide Drug Conjugates (RDC) Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Radionuclide Drug Conjugates (RDC) Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Radionuclide Drug Conjugates (RDC) Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Radionuclide Drug Conjugates (RDC) Players in 2022
Table 12. World Radionuclide Drug Conjugates (RDC) Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Radionuclide Drug Conjugates (RDC) Company Evaluation Quadrant
Table 14. Head Office of Key Radionuclide Drug Conjugates (RDC) Player
Table 15. Radionuclide Drug Conjugates (RDC) Market: Company Product Type Footprint
Table 16. Radionuclide Drug Conjugates (RDC) Market: Company Product Application Footprint
Table 17. Radionuclide Drug Conjugates (RDC) Mergers & Acquisitions Activity
Table 18. United States VS China Radionuclide Drug Conjugates (RDC) Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Radionuclide Drug Conjugates (RDC) Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Radionuclide Drug Conjugates (RDC) Companies, Headquarters (States, Country)
Table 21. United States Based Companies Radionuclide Drug Conjugates (RDC) Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Radionuclide Drug Conjugates (RDC) Revenue Market Share (2018-2023)
Table 23. China Based Radionuclide Drug Conjugates (RDC) Companies, Headquarters (Province, Country)
Table 24. China Based Companies Radionuclide Drug Conjugates (RDC) Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Radionuclide Drug Conjugates (RDC) Revenue Market Share (2018-2023)
Table 26. Rest of World Based Radionuclide Drug Conjugates (RDC) Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Radionuclide Drug Conjugates (RDC) Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Radionuclide Drug Conjugates (RDC) Revenue Market Share (2018-2023)
Table 29. World Radionuclide Drug Conjugates (RDC) Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023) & (USD Million)
Table 31. World Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2029) & (USD Million)
Table 32. World Radionuclide Drug Conjugates (RDC) Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023) & (USD Million)
Table 34. World Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2029) & (USD Million)
Table 35. POINT Biopharma Basic Information, Area Served and Competitors
Table 36. POINT Biopharma Major Business
Table 37. POINT Biopharma Radionuclide Drug Conjugates (RDC) Product and Services
Table 38. POINT Biopharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. POINT Biopharma Recent Developments/Updates
Table 40. POINT Biopharma Competitive Strengths & Weaknesses
Table 41. Telix Basic Information, Area Served and Competitors
Table 42. Telix Major Business
Table 43. Telix Radionuclide Drug Conjugates (RDC) Product and Services
Table 44. Telix Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Telix Recent Developments/Updates
Table 46. Telix Competitive Strengths & Weaknesses
Table 47. ITM AG Basic Information, Area Served and Competitors
Table 48. ITM AG Major Business
Table 49. ITM AG Radionuclide Drug Conjugates (RDC) Product and Services
Table 50. ITM AG Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. ITM AG Recent Developments/Updates
Table 52. ITM AG Competitive Strengths & Weaknesses
Table 53. Bayer AG Basic Information, Area Served and Competitors
Table 54. Bayer AG Major Business
Table 55. Bayer AG Radionuclide Drug Conjugates (RDC) Product and Services
Table 56. Bayer AG Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Bayer AG Recent Developments/Updates
Table 58. Bayer AG Competitive Strengths & Weaknesses
Table 59. Novartis Basic Information, Area Served and Competitors
Table 60. Novartis Major Business
Table 61. Novartis Radionuclide Drug Conjugates (RDC) Product and Services
Table 62. Novartis Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Novartis Recent Developments/Updates
Table 64. Novartis Competitive Strengths & Weaknesses
Table 65. Lantheus Basic Information, Area Served and Competitors
Table 66. Lantheus Major Business
Table 67. Lantheus Radionuclide Drug Conjugates (RDC) Product and Services
Table 68. Lantheus Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Lantheus Recent Developments/Updates
Table 70. Lantheus Competitive Strengths & Weaknesses
Table 71. Curium Pharma Basic Information, Area Served and Competitors
Table 72. Curium Pharma Major Business
Table 73. Curium Pharma Radionuclide Drug Conjugates (RDC) Product and Services
Table 74. Curium Pharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Curium Pharma Recent Developments/Updates
Table 76. Curium Pharma Competitive Strengths & Weaknesses
Table 77. Uihc Pet Imaging Basic Information, Area Served and Competitors
Table 78. Uihc Pet Imaging Major Business
Table 79. Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Product and Services
Table 80. Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Uihc Pet Imaging Recent Developments/Updates
Table 82. Uihc Pet Imaging Competitive Strengths & Weaknesses
Table 83. Grand Pharma Basic Information, Area Served and Competitors
Table 84. Grand Pharma Major Business
Table 85. Grand Pharma Radionuclide Drug Conjugates (RDC) Product and Services
Table 86. Grand Pharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Grand Pharma Recent Developments/Updates
Table 88. Grand Pharma Competitive Strengths & Weaknesses
Table 89. BoomRay Pharmaceuticals Basic Information, Area Served and Competitors
Table 90. BoomRay Pharmaceuticals Major Business
Table 91. BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Product and Services
Table 92. BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. BoomRay Pharmaceuticals Recent Developments/Updates
Table 94. BoomRay Pharmaceuticals Competitive Strengths & Weaknesses
Table 95. SmartNuclide Biopharma Basic Information, Area Served and Competitors
Table 96. SmartNuclide Biopharma Major Business
Table 97. SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Product and Services
Table 98. SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. SmartNuclide Biopharma Recent Developments/Updates
Table 100. SmartNuclide Biopharma Competitive Strengths & Weaknesses
Table 101. Hengrui Medicine Basic Information, Area Served and Competitors
Table 102. Hengrui Medicine Major Business
Table 103. Hengrui Medicine Radionuclide Drug Conjugates (RDC) Product and Services
Table 104. Hengrui Medicine Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Hengrui Medicine Recent Developments/Updates
Table 106. Hengrui Medicine Competitive Strengths & Weaknesses
Table 107. Yunnan Baiyao Group Basic Information, Area Served and Competitors
Table 108. Yunnan Baiyao Group Major Business
Table 109. Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Product and Services
Table 110. Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Yunnan Baiyao Group Recent Developments/Updates
Table 112. Yunnan Baiyao Group Competitive Strengths & Weaknesses
Table 113. Sinotau Basic Information, Area Served and Competitors
Table 114. Sinotau Major Business
Table 115. Sinotau Radionuclide Drug Conjugates (RDC) Product and Services
Table 116. Sinotau Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Sinotau Recent Developments/Updates
Table 118. Sinotau Competitive Strengths & Weaknesses
Table 119. Hexin Pharmaceutical Basic Information, Area Served and Competitors
Table 120. Hexin Pharmaceutical Major Business
Table 121. Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Product and Services
Table 122. Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Hexin Pharmaceutical Recent Developments/Updates
Table 124. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Basic Information, Area Served and Competitors
Table 125. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Major Business
Table 126. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Product and Services
Table 127. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 128. Global Key Players of Radionuclide Drug Conjugates (RDC) Upstream (Raw Materials)
Table 129. Radionuclide Drug Conjugates (RDC) Typical Customers
Table 1. World Radionuclide Drug Conjugates (RDC) Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Radionuclide Drug Conjugates (RDC) Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Radionuclide Drug Conjugates (RDC) Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Radionuclide Drug Conjugates (RDC) Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Radionuclide Drug Conjugates (RDC) Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Radionuclide Drug Conjugates (RDC) Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Radionuclide Drug Conjugates (RDC) Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Radionuclide Drug Conjugates (RDC) Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Radionuclide Drug Conjugates (RDC) Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Radionuclide Drug Conjugates (RDC) Players in 2022
Table 12. World Radionuclide Drug Conjugates (RDC) Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Radionuclide Drug Conjugates (RDC) Company Evaluation Quadrant
Table 14. Head Office of Key Radionuclide Drug Conjugates (RDC) Player
Table 15. Radionuclide Drug Conjugates (RDC) Market: Company Product Type Footprint
Table 16. Radionuclide Drug Conjugates (RDC) Market: Company Product Application Footprint
Table 17. Radionuclide Drug Conjugates (RDC) Mergers & Acquisitions Activity
Table 18. United States VS China Radionuclide Drug Conjugates (RDC) Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Radionuclide Drug Conjugates (RDC) Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Radionuclide Drug Conjugates (RDC) Companies, Headquarters (States, Country)
Table 21. United States Based Companies Radionuclide Drug Conjugates (RDC) Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Radionuclide Drug Conjugates (RDC) Revenue Market Share (2018-2023)
Table 23. China Based Radionuclide Drug Conjugates (RDC) Companies, Headquarters (Province, Country)
Table 24. China Based Companies Radionuclide Drug Conjugates (RDC) Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Radionuclide Drug Conjugates (RDC) Revenue Market Share (2018-2023)
Table 26. Rest of World Based Radionuclide Drug Conjugates (RDC) Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Radionuclide Drug Conjugates (RDC) Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Radionuclide Drug Conjugates (RDC) Revenue Market Share (2018-2023)
Table 29. World Radionuclide Drug Conjugates (RDC) Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023) & (USD Million)
Table 31. World Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2029) & (USD Million)
Table 32. World Radionuclide Drug Conjugates (RDC) Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023) & (USD Million)
Table 34. World Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2029) & (USD Million)
Table 35. POINT Biopharma Basic Information, Area Served and Competitors
Table 36. POINT Biopharma Major Business
Table 37. POINT Biopharma Radionuclide Drug Conjugates (RDC) Product and Services
Table 38. POINT Biopharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. POINT Biopharma Recent Developments/Updates
Table 40. POINT Biopharma Competitive Strengths & Weaknesses
Table 41. Telix Basic Information, Area Served and Competitors
Table 42. Telix Major Business
Table 43. Telix Radionuclide Drug Conjugates (RDC) Product and Services
Table 44. Telix Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Telix Recent Developments/Updates
Table 46. Telix Competitive Strengths & Weaknesses
Table 47. ITM AG Basic Information, Area Served and Competitors
Table 48. ITM AG Major Business
Table 49. ITM AG Radionuclide Drug Conjugates (RDC) Product and Services
Table 50. ITM AG Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. ITM AG Recent Developments/Updates
Table 52. ITM AG Competitive Strengths & Weaknesses
Table 53. Bayer AG Basic Information, Area Served and Competitors
Table 54. Bayer AG Major Business
Table 55. Bayer AG Radionuclide Drug Conjugates (RDC) Product and Services
Table 56. Bayer AG Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Bayer AG Recent Developments/Updates
Table 58. Bayer AG Competitive Strengths & Weaknesses
Table 59. Novartis Basic Information, Area Served and Competitors
Table 60. Novartis Major Business
Table 61. Novartis Radionuclide Drug Conjugates (RDC) Product and Services
Table 62. Novartis Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Novartis Recent Developments/Updates
Table 64. Novartis Competitive Strengths & Weaknesses
Table 65. Lantheus Basic Information, Area Served and Competitors
Table 66. Lantheus Major Business
Table 67. Lantheus Radionuclide Drug Conjugates (RDC) Product and Services
Table 68. Lantheus Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Lantheus Recent Developments/Updates
Table 70. Lantheus Competitive Strengths & Weaknesses
Table 71. Curium Pharma Basic Information, Area Served and Competitors
Table 72. Curium Pharma Major Business
Table 73. Curium Pharma Radionuclide Drug Conjugates (RDC) Product and Services
Table 74. Curium Pharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Curium Pharma Recent Developments/Updates
Table 76. Curium Pharma Competitive Strengths & Weaknesses
Table 77. Uihc Pet Imaging Basic Information, Area Served and Competitors
Table 78. Uihc Pet Imaging Major Business
Table 79. Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Product and Services
Table 80. Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Uihc Pet Imaging Recent Developments/Updates
Table 82. Uihc Pet Imaging Competitive Strengths & Weaknesses
Table 83. Grand Pharma Basic Information, Area Served and Competitors
Table 84. Grand Pharma Major Business
Table 85. Grand Pharma Radionuclide Drug Conjugates (RDC) Product and Services
Table 86. Grand Pharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Grand Pharma Recent Developments/Updates
Table 88. Grand Pharma Competitive Strengths & Weaknesses
Table 89. BoomRay Pharmaceuticals Basic Information, Area Served and Competitors
Table 90. BoomRay Pharmaceuticals Major Business
Table 91. BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Product and Services
Table 92. BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. BoomRay Pharmaceuticals Recent Developments/Updates
Table 94. BoomRay Pharmaceuticals Competitive Strengths & Weaknesses
Table 95. SmartNuclide Biopharma Basic Information, Area Served and Competitors
Table 96. SmartNuclide Biopharma Major Business
Table 97. SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Product and Services
Table 98. SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. SmartNuclide Biopharma Recent Developments/Updates
Table 100. SmartNuclide Biopharma Competitive Strengths & Weaknesses
Table 101. Hengrui Medicine Basic Information, Area Served and Competitors
Table 102. Hengrui Medicine Major Business
Table 103. Hengrui Medicine Radionuclide Drug Conjugates (RDC) Product and Services
Table 104. Hengrui Medicine Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Hengrui Medicine Recent Developments/Updates
Table 106. Hengrui Medicine Competitive Strengths & Weaknesses
Table 107. Yunnan Baiyao Group Basic Information, Area Served and Competitors
Table 108. Yunnan Baiyao Group Major Business
Table 109. Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Product and Services
Table 110. Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Yunnan Baiyao Group Recent Developments/Updates
Table 112. Yunnan Baiyao Group Competitive Strengths & Weaknesses
Table 113. Sinotau Basic Information, Area Served and Competitors
Table 114. Sinotau Major Business
Table 115. Sinotau Radionuclide Drug Conjugates (RDC) Product and Services
Table 116. Sinotau Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Sinotau Recent Developments/Updates
Table 118. Sinotau Competitive Strengths & Weaknesses
Table 119. Hexin Pharmaceutical Basic Information, Area Served and Competitors
Table 120. Hexin Pharmaceutical Major Business
Table 121. Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Product and Services
Table 122. Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Hexin Pharmaceutical Recent Developments/Updates
Table 124. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Basic Information, Area Served and Competitors
Table 125. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Major Business
Table 126. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Product and Services
Table 127. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 128. Global Key Players of Radionuclide Drug Conjugates (RDC) Upstream (Raw Materials)
Table 129. Radionuclide Drug Conjugates (RDC) Typical Customers
LIST OF FIGURES
Figure 1. Radionuclide Drug Conjugates (RDC) Picture
Figure 2. World Radionuclide Drug Conjugates (RDC) Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Radionuclide Drug Conjugates (RDC) Total Market Size (2018-2029) & (USD Million)
Figure 4. World Radionuclide Drug Conjugates (RDC) Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Radionuclide Drug Conjugates (RDC) Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 13. Radionuclide Drug Conjugates (RDC) Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 16. World Radionuclide Drug Conjugates (RDC) Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 18. China Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 23. India Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Radionuclide Drug Conjugates (RDC) by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Radionuclide Drug Conjugates (RDC) Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Radionuclide Drug Conjugates (RDC) Markets in 2022
Figure 27. United States VS China: Radionuclide Drug Conjugates (RDC) Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Radionuclide Drug Conjugates (RDC) Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Radionuclide Drug Conjugates (RDC) Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type in 2022
Figure 31. Antibody Radionuclide Conjugates (ARC)
Figure 32. Peptide Radionuclide Conjugates (PRC)
Figure 33. Small Molecular Radionuclide Conjugates (SMRC)
Figure 34. World Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2018-2029)
Figure 35. World Radionuclide Drug Conjugates (RDC) Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application in 2022
Figure 37. Neuroendocrine Tumors
Figure 38. Prostate Cancer
Figure 39. Renal Cell Carcinoma
Figure 40. Radionuclide Drug Conjugates (RDC) Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
Figure 1. Radionuclide Drug Conjugates (RDC) Picture
Figure 2. World Radionuclide Drug Conjugates (RDC) Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Radionuclide Drug Conjugates (RDC) Total Market Size (2018-2029) & (USD Million)
Figure 4. World Radionuclide Drug Conjugates (RDC) Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Radionuclide Drug Conjugates (RDC) Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Radionuclide Drug Conjugates (RDC) Revenue (2018-2029) & (USD Million)
Figure 13. Radionuclide Drug Conjugates (RDC) Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 16. World Radionuclide Drug Conjugates (RDC) Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 18. China Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 23. India Radionuclide Drug Conjugates (RDC) Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Radionuclide Drug Conjugates (RDC) by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Radionuclide Drug Conjugates (RDC) Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Radionuclide Drug Conjugates (RDC) Markets in 2022
Figure 27. United States VS China: Radionuclide Drug Conjugates (RDC) Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Radionuclide Drug Conjugates (RDC) Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Radionuclide Drug Conjugates (RDC) Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type in 2022
Figure 31. Antibody Radionuclide Conjugates (ARC)
Figure 32. Peptide Radionuclide Conjugates (PRC)
Figure 33. Small Molecular Radionuclide Conjugates (SMRC)
Figure 34. World Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2018-2029)
Figure 35. World Radionuclide Drug Conjugates (RDC) Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application in 2022
Figure 37. Neuroendocrine Tumors
Figure 38. Prostate Cancer
Figure 39. Renal Cell Carcinoma
Figure 40. Radionuclide Drug Conjugates (RDC) Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
